NBRV
Income statement / Annual
Last year (2022), Nabriva Therapeutics plc's total revenue was $35.67 M,
an increase of 31.06% from the previous year.
In 2022, Nabriva Therapeutics plc's net income was -$57.19 M.
See Nabriva Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$35.67 M |
$27.22 M |
$2.86 M |
$7.75 M |
$6.50 M |
$0.00 |
$0.00 |
$84.00 K |
$0.00 |
$0.00 |
| Cost of Revenue |
$28.58 M
|
$13.15 M
|
$766.00 K
|
$70.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$7.09 M
|
$14.07 M
|
$2.10 M
|
$7.68 M
|
$6.50 M
|
$0.00
|
$0.00
|
$84.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.2
|
0.52
|
0.73
|
0.99
|
1
|
0
|
0
|
1
|
0
|
0
|
| Research and Development Expenses |
$14.26 M
|
$12.63 M
|
$15.10 M
|
$26.42 M
|
$82.29 M
|
$49.62 M
|
$47.99 M
|
$20.79 M
|
$8.59 M
|
$10.11 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$41.74 M
|
$29.47 M
|
$13.44 M
|
$7.82 M
|
$3.46 M
|
$3.92 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$45.26 M
|
$51.65 M
|
$55.29 M
|
$62.49 M
|
$41.74 M
|
$29.47 M
|
$13.44 M
|
$7.82 M
|
$3.46 M
|
$3.92 M
|
| Other Expenses |
-$1.27 M
|
-$1.68 M
|
-$2.16 M
|
-$1.73 M
|
-$272.00 K
|
$492.00 K
|
$55.00 K
|
$2.86 M
|
$77.82 K
|
$34.30 M
|
| Operating Expenses |
$58.26 M
|
$62.60 M
|
$68.22 M
|
$87.17 M
|
$120.88 M
|
$73.77 M
|
$61.53 M
|
$26.84 M
|
$9.89 M
|
$6.74 M
|
| Cost And Expenses |
$86.84 M
|
$75.74 M
|
$68.99 M
|
$87.24 M
|
$120.88 M
|
$73.77 M
|
$55.05 M
|
$26.84 M
|
$9.89 M
|
$6.74 M
|
| Interest Income |
$0.00
|
$0.00
|
$86.00 K
|
$255.00 K
|
$49.00 K
|
$318.00 K
|
$343.00 K
|
$6.74 M
|
$2.43 K
|
$307.93 K
|
| Interest Expense |
$698.00 K
|
$0.00
|
$1.74 M
|
$3.64 M
|
$133.00 K
|
$43.00 K
|
$75.00 K
|
$14.59 M
|
$6.99 M
|
$5.55 M
|
| Depreciation & Amortization |
-$3.53 M
|
$637.00 K
|
$820.00 K
|
$470.00 K
|
$510.00 K
|
$432.00 K
|
$233.00 K
|
$150.88 K
|
$152.00 K
|
$197.46 K
|
| EBITDA |
-$54.70 M |
-$49.22 M |
-$66.79 M |
-$78.55 M |
-$114.09 M |
-$72.53 M |
-$54.42 M |
-$17.24 M |
-$9.75 M |
$28.06 M |
| EBITDA Ratio |
-1.53
|
-1.81
|
-23.32
|
-10.14
|
-17.55
|
0
|
0
|
-205.19
|
0
|
0
|
| Operating Income Ratio |
-1.56
|
-1.78
|
-23.09
|
-10.26
|
-17.6
|
0
|
0
|
-285.44
|
0
|
0
|
| Total Other Income/Expenses Net |
-$4.44 M
|
-$432.00 K
|
-$3.22 M
|
-$3.17 M
|
-$356.00 K
|
$767.00 K
|
-$515.00 K
|
$2.86 M
|
-$6.42 M
|
-$5.76 M
|
| Income Before Tax |
-$55.62 M
|
-$48.96 M
|
-$69.35 M
|
-$82.66 M
|
-$114.73 M
|
-$73.00 M
|
-$55.56 M
|
-$31.83 M
|
-$16.18 M
|
$16.55 M
|
| Income Before Tax Ratio |
-1.56
|
-1.8
|
-24.21
|
-10.67
|
-17.65
|
0
|
0
|
-378.87
|
0
|
0
|
| Income Tax Expense |
$1.57 M
|
$490.00 K
|
$139.00 K
|
$101.00 K
|
$49.00 K
|
$1.36 M
|
-$672.00 K
|
-$438.00 K
|
$87.55 K
|
$1.07 M
|
| Net Income |
-$57.19 M
|
-$49.45 M
|
-$69.48 M
|
-$82.76 M
|
-$114.78 M
|
-$74.36 M
|
-$54.89 M
|
-$31.39 M
|
-$16.27 M
|
$15.48 M
|
| Net Income Ratio |
-1.6
|
-1.82
|
-24.26
|
-10.68
|
-17.66
|
0
|
0
|
-373.65
|
0
|
0
|
| EPS |
-21.32 |
-28.52 |
-135.23 |
-278.75 |
-564.91 |
-623.15 |
-638.9 |
-741.38 |
-149.52 |
142.25 |
| EPS Diluted |
-21.32 |
-28.52 |
-135.23 |
-278.75 |
-564.91 |
-623.15 |
-638.9 |
-1200 |
-149.52 |
130.92 |
| Weighted Average Shares Out |
$2.68 M
|
$1.73 M
|
$513.80 K
|
$296.80 K
|
$203.18 K
|
$119.32 K
|
$85.91 K
|
$42.34 K
|
$108.82 K
|
$108.82 K
|
| Weighted Average Shares Out Diluted |
$2.68 M
|
$1.73 M
|
$513.80 K
|
$296.80 K
|
$203.18 K
|
$119.32 K
|
$85.91 K
|
$42.34 K
|
$108.82 K
|
$108.82 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
